InstantGMP has joined hands with Corsair Pharma, a biopharmaceutical company focused on enhancing the effectiveness of medications to create improved treatment options for patients with complex medical needs.

Corsair Pharma is revolutionizing pulmonary arterial hypertension (PAH) treatment with its first product candidate: a prodrug of treprostinil delivered via a proprietary transdermal patch.

As they prepare for Phase One clinical trials, Corsair Pharma is prioritizing safety, tolerability, and quality at every stage of development. To support these critical goals, the company has transitioned from a paper-based system to InstantGMP's Quality Management System (QMS) and Document Management System (DMS) modules.

Additionally, InstantGMP's modular design ensures Corsair Pharma can easily expand its system to include additional functionalities such as the Electronic Batch Record Module and Inventory Management Module. This flexibility positions Corsair Pharma for success as they scale their operations and assume greater manufacturing responsibilities.

"As Corsair Pharma transitions into Phase One clinical trials, safety and quality are our highest priorities. InstantGMP's QMS and DMS modules provide us with the tools we need to ensure safety, maintain compliance, streamline our operations, and focus on delivering transformative solutions for our patients. We're confident that this partnership will be instrumental in our success," said Jason Vines, Quality Manager at Corsair Pharma.